AMENDMENTS TO THE CLAIMS

This listing replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (Previously Presented) A pharmaceutical composition useful for treating a hematological cancer in a mammal, consisting essentially of (A) at least one arsenic sulfide compound, (B) a pharmaceutically acceptable carrier or excipient, and optionally (C) an effective amount of a therapeutic agent selected from the group consisting of mustard compounds, nitrogen mustard, chliorambucil, melphalan, cyclophosphamide busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.

2- 4. (Canceled)

5. (Original) The pharmaceutical composition of claim 1, wherein said mammal is a human.

6. (Original) The pharmaceutical composition of claim 1, wherein the arsenic sulfide compound is selected from the group consisting of As_2S_2, As_2S_3, As_2S_5 and As_4S_4.

7. (Original) The pharmaceutical composition of claim 6, wherein the arsenic sulfide compound is As_4S_4.

8. (Original) The pharmaceutical composition of claim 1, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.

9. (Previously Presented) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier or excipient is a plant semen.

10. (Previously Presented) The pharmaceutical composition of claim 1, wherein the plant semen is *Seman platycladi*.

11.-59. (Canceled)

60. (Previously Presented) The composition of claim 1, wherein the hematological cancer is selected from the group consisting of acute lymphoblastic leukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute nonlymphoblastic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, chronic myelocytic leukemia, myelodysplastic syndrome, refractory anemia with excessive blast (RAEB) and RAEB in transformation to leukemia (RAEB-T), and chronic myelo-monocytic leukemia.

61. (Previously Presented) The composition of claim 1, wherein the pharmaceutical composition is formulated for oral delivery to a human.

62. (Canceled)